These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 10762560)
1. Use of herpes simplex virus (HSV) type 1 ISCOMS 703 vaccine for prophylactic and therapeutic treatment of primary and recurrent HSV-2 infection in guinea pigs. Simms JR; Heath AW; Jennings R J Infect Dis; 2000 Apr; 181(4):1240-8. PubMed ID: 10762560 [TBL] [Abstract][Full Text] [Related]
2. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection. Da Costa XJ; Morrison LA; Knipe DM Virology; 2001 Sep; 288(2):256-63. PubMed ID: 11601897 [TBL] [Abstract][Full Text] [Related]
3. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs. Bourne N; Bravo FJ; Francotte M; Bernstein DI; Myers MG; Slaoui M; Stanberry LR J Infect Dis; 2003 Feb; 187(4):542-9. PubMed ID: 12599070 [TBL] [Abstract][Full Text] [Related]
4. Construction and characterization of a replication-defective herpes simplex virus 2 ICP8 mutant strain and its use in immunization studies in a guinea pig model of genital disease. Da Costa XJ; Bourne N; Stanberry LR; Knipe DM Virology; 1997 May; 232(1):1-12. PubMed ID: 9185583 [TBL] [Abstract][Full Text] [Related]
5. Enhancement of protective humoral immune responses against Herpes simplex virus-2 in DNA-immunized guinea-pigs using protein boosting. Fotouhi F; Soleimanjahi H; Roostaee MH; Behzadian F FEMS Immunol Med Microbiol; 2008 Oct; 54(1):18-26. PubMed ID: 18647350 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic periocular vaccination with a subunit vaccine induces higher levels of herpes simplex virus-specific tear secretory immunoglobulin A than systemic vaccination and provides protection against recurrent spontaneous ocular shedding of virus in latently infected rabbits. Nesburn AB; Burke RL; Ghiasi H; Slanina SM; Wechsler SL Virology; 1998 Dec; 252(1):200-9. PubMed ID: 9875329 [TBL] [Abstract][Full Text] [Related]
7. Effect of immunization with herpes simplex virus type-1 (HSV-1) glycoprotein D (gD) plus the immune enhancer GPI-0100 on infection with HSV-1 or HSV-2. Quenelle DC; Collins DJ; Marciani DJ; Kern ER Vaccine; 2006 Mar; 24(10):1515-22. PubMed ID: 16288820 [TBL] [Abstract][Full Text] [Related]
8. Recombinant interleukin 2 as an adjuvant for vaccine-induced protection. Immunization of guinea pigs with herpes simplex virus subunit vaccines. Weinberg A; Merigan TC J Immunol; 1988 Jan; 140(1):294-9. PubMed ID: 2826591 [TBL] [Abstract][Full Text] [Related]
9. Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected. Bourne N; Milligan GN; Stanberry LR; Stegall R; Pyles RB J Infect Dis; 2005 Dec; 192(12):2117-23. PubMed ID: 16288376 [TBL] [Abstract][Full Text] [Related]
10. The HSV-1 live attenuated VC2 vaccine provides protection against HSV-2 genital infection in the guinea pig model of genital herpes. Bernstein DI; Pullum DA; Cardin RD; Bravo FJ; Dixon DA; Kousoulas KG Vaccine; 2019 Jan; 37(1):61-68. PubMed ID: 30471955 [TBL] [Abstract][Full Text] [Related]
11. A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens. Awasthi S; Mahairas GG; Shaw CE; Huang ML; Koelle DM; Posavad C; Corey L; Friedman HM J Virol; 2015 Aug; 89(16):8497-509. PubMed ID: 26041292 [TBL] [Abstract][Full Text] [Related]
12. Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment. Bernstein DI; Harrison CJ; Tomai MA; Miller RL J Infect Dis; 2001 Mar; 183(6):844-9. PubMed ID: 11237799 [TBL] [Abstract][Full Text] [Related]
13. Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines. Stanberry LR Herpes; 2004 Aug; 11 Suppl 3():161A-169A. PubMed ID: 15319086 [TBL] [Abstract][Full Text] [Related]
14. Vaccination with the Secreted Glycoprotein G of Herpes Simplex Virus 2 Induces Protective Immunity after Genital Infection. Önnheim K; Ekblad M; Görander S; Bergström T; Liljeqvist JÅ Viruses; 2016 Apr; 8(4):110. PubMed ID: 27110813 [TBL] [Abstract][Full Text] [Related]
15. A growth and latency compromised herpes simplex virus type 2 mutant (ICP10DeltaPK) has prophylactic and therapeutic protective activity in guinea pigs. Wachsman M; Kulka M; Smith CC; Aurelian L Vaccine; 2001 Feb; 19(15-16):1879-90. PubMed ID: 11228357 [TBL] [Abstract][Full Text] [Related]
16. Vaccination strategies to prevent genital herpes and neonatal herpes simplex virus (HSV) disease. Jones CA; Cunningham AL Herpes; 2004 Apr; 11(1):12-7. PubMed ID: 15115632 [TBL] [Abstract][Full Text] [Related]
17. Preparation and efficacy of antiherpes type 1 and 2 subunit vaccines. Kavaklova L; Dundarov S; Andonov P; Bakalov B; Dundarova D; Brodvarova I Acta Virol; 1986 Sep; 30(5):402-10. PubMed ID: 2878588 [TBL] [Abstract][Full Text] [Related]
18. Immune responses in mice induced by HSV-1 glycoproteins presented with ISCOMs or NISV delivery systems. Hassan Y; Brewer JM; Alexander J; Jennings R Vaccine; 1996 Dec; 14(17-18):1581-9. PubMed ID: 9032885 [TBL] [Abstract][Full Text] [Related]
19. Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigs. Bernard MC; Barban V; Pradezynski F; de Montfort A; Ryall R; Caillet C; Londono-Hayes P PLoS One; 2015; 10(4):e0121518. PubMed ID: 25837802 [TBL] [Abstract][Full Text] [Related]
20. A vaccine containing highly purified virus particles in adjuvant provides high level protection against genital infection and disease in guinea pigs challenged intravaginally with homologous and heterologous strains of herpes simplex virus type 2. Bernstein DI; Morello CS; Cardin RD; Bravo FJ; Kraynyak KA; Spector DH Vaccine; 2020 Jan; 38(1):79-89. PubMed ID: 31611098 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]